Radical therapy for muscle-infiltrating bladder cancer (cystectomy or radiotherapy): Does age affect the final therapeutic benefit for the patient?

Journal of B.U.ON.

Volumn 13, Issue 3, 2008, Pages 353-358

  Kalogeras, Dimitrios A ^a,b   Lampri, E ^a   Goussia, A ^a   Bai, M ^a   Capizzello, A ^a   Tassiou, I ^a   Stavropoulos, N E ^a   Tsekeris, P ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b University Hospital of Ioannina ^*  (Greece)

Author keywords

Age; Bladder cancer; Cystectomy; Muscle infiltrating; Radiotherapy; Survival

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; HUMAN; MAJOR CLINICAL STUDY; MUSCLE METASTASIS; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; RADIATION SICKNESS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

AGE FACTORS; AGED; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MUSCLE NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 53849125073     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. U.S. Bureau of Census. Census US Gov: projections of the population of the United States by age, sex and race, 1988-2080, current population reports, population estimates and projections series, p 25, Washington, D.C.: U.5. Bureau of Census, U.S. Department of Commerce, 1991, pp 1-25.
2. Jakse G, Algaba F, Fossa S, Stenzl A, Stenberg C. European Association of Urology (EAU). Guidelines on Bladder Cancer, Muscle-invasive and Metastatic. EAU Guidelines 2008, pp 4-7.
3. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder: ten-year outcome. J Clin Oncol 1998; 16: 1298-1301.
4. Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle invasive bladder cancer: future alternatives to radical cystectomy. Ann Med 2000; 32: 34-42.
5. Bower M, Ma R, Savage P, Abel P, Waxman J. British urological surgery practice: 2. Renal, bladder and testis cancer. Br J Urol 1998; 81: 513-517.
6. Herr HW, Bajorin D, Scher H, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol 1999; 161: 20-22.
7. Holmang S, Hedelin H, Anderstrom C, Johansson SL. Long-term follow up of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol 1997; 158: 389-392.
8. Ghoneim MA, El-Mekresh MM, El-Baz MA, El-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997; 158: 393-399.
9. Frazier HA, Robertson JE, Dodge RK, Paulson DF. The value of pathologic factors in predicting cancer specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71: 3993-4001.
10. Bassi P, Ferrante GD, Piazza N et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. Urology 1999; 161: 1494-1497.
11. Bernardini S, Adessi GL, Billery C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 1999; 62: 1496-1501.
12. Gao JP, Uchida T, Wang C et al. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol 2000; 16: 469-475.
13. Toktas G, Turkeri LN, Unluer E et al. Prognostic significance of p53 protein accumulation in stage pT1 transitional cell carcinoma of the bladder. Int Urol Nephrol 1999; 31: 437-441.
14. EORTC-GU Group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle invasive bladder cancer: a randomised controlled trial. Lancet 1999; 354: 533-540.
15. Hellsten S, Rintala E, Wahlqvist R, Malmstrom PU. Nordic prospective trials of radical cystectomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer Study Group. Eur Urol 1998; 33 (Suppl 4): 35-38.
16. Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derived derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40: 121-127.
17. Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16: 3576-3583.
18. Coppin CML, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-2907.
19. Thrasher JB, Frazier HA, Robertson JE, Paulson DF. Does stage pT0 cystectomy specimen confers a survival advantage in patients with minimally invasive bladder cancer. J Urol 1994; 152: 393-396.
20. Stein JP, Esrig D, Freeman JA et al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology 1998; 51: 951-955.
21. Lerner SP, Skinner DG, Lieskovsky G et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol 1993; 149: 758-765.
22. Kachnic LA, Kaufmann DS, Heney EM et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 1022-1099.
23. Stein P, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-675.
24. Joulie M, Straub M, Game X et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol 2002; 167 (Suppl): 132S-138S.
25. Chang SS, Alberts G, Cookson MS et al. Radical cystectomy is safe in elderly patients at high risk. J Urol 2001; 166: 938-941.
26. Thrasher JB, Frazier HA, Robertson JE et al. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1994; 73: 1708-1715.
27. Clark PE, Stein P, Groshen G et al. Radical cystectomy in the elderly: comparison of survival between younger and older patients. Cancer 2005; 103: 546-552.
28. Hollenbeck BK, Miller DC, Taub D et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology 2004; 64: 292-297.
29. Waehre H, Ous S, Klevmark B et al. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 1993; 72: 3044-3051.
30. Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991; 21: 163-170.
31. De Neve W, Lybeert MLM, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995; 36: 183-188.
32. Shelley MD, Barber J, Wilt T, Mason MD. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002; (1): CD002079.
33. Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-3071.
34. Johnson DE, Lamy SM. Complications of a single stage radical cystectomy and ileal conduit diversion: review of 214 cases. J Urol 1977; 117: 171-173.
35. Frazier HA, Robertson JE, Paulson DF. Complications of radical cystectomy and urinary diversion: a retrospective review of 675 cases in 2 decades. J Urol 1992; 148: 1401-1405.
36. Mundy AR, Nurse DE, Dick JA, Murray KH. Continence and potency preserving cystoprostatectomy and substitution cystoplasty for patients with bladder cancer. Br J Urol 1986; 58: 664-668.
37. Bjerre BD, Johansen C, Steven K. Sexological problems after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire study of male patients. Scand J Urol Nephrol 1998; 32: 187-193.
38. Pagano F, Bassi P, Galetti TP et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145: 45-50.
39. Wijkstrom H, Norming U, Lagerkvist M, Nilsson B, Naslund I, Wiklund P. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br J Urol 1998; 81: 686-691.
40. Haleblian GE, Skinner EC, Dickinson MG, Lieskovsky G, Boyd SD, Skinner DG. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol 1998; 160: 2011-2014.
41. Herr HW. Routine CT scan in cystectomy patients: does it change management? Urology 1996; 47: 324-325.
42. Tavares NJ, Demas BE, Hricak H. MR imaging of bladder neoplasms: correlation with pathologic staging. Urol Radiol 1990; 12: 27-33.